Hematologic Neoplasms
109
20
23
57
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Published Results
19 trials with published results (17%)
Research Maturity
57 completed trials (52% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
6.4%
7 terminated out of 109 trials
89.1%
+2.5% vs benchmark
11%
12 trials in Phase 3/4
33%
19 of 57 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 57 completed trials
Clinical Trials (109)
Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members
Influenza Vaccination Strategy for Patients With Hematologic Malignancy
A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
Ceftazidime-Avibactam PK/PD and Resistance in Hematology Patients
Anti-CD25 Monoclonal Antibody for Prevention of Acute GVHD After Haploidentical HSCT
Take5Care+: A Self-management Educational Intervention
Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms
Fludarabine and Total Body Irradiation 800 Centigray (cGy) or 1125 cGy For Allogeneic Stem Cell Transplant Using Graft Versus Host Disease Prophylaxis With Post-Transplant Cyclophosphamide and Tacrolimus, Without Mycophenolate Mofetil
Cognitive Training Intervention and Attitudes Towards Genetics
LLM-Generated Plain-Language Patient Synopses to Improve Comprehension in Hematology and Oncology (oncOPAL)
Mind-body Medicine for Patients With Malignant Hematological Diseases
UWCCC Molecular Tumor Board Registry
Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
Research Development13(RD13)-02 Cell Injection in Patients With Relapsed or Refractory Cluster Of Differentiation 7(CD7)-Positive Hematological Malignancies
Platelet Transfusions in Hematopoietic Stem Cell Transplantation (The PATH III Trial)
Comparison of Hemanext ONE® System and Conventional Red Blood Cell Transfusion